FDA grants orphan drug designation to devimistat for soft tissue sarcoma
The U.S. Food and Drug Administration has granted orphan drug designation for CPI-613® (devimistat; Rafael Pharmaceuticals, Inc) for the treatment of soft tissue sarcoma.
“There is a significant unmet need in treatment for soft tissue sarcoma,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals in a press release. “When a disease is rare, it often does not receive the attention and focus necessary to develop effective treatments for it. We want to be a voice for those diagnosed with hard-to-treat cancers so that they know that they are not forgotten. We are focusing our attention on developing treatments for these cancers. In fact, Rafael is one of the only companies working on a treatment for clear cell sarcoma.”
Read the full press release here.